Controlling Pseudorabies/Aujeszky's disease in vaccinated swine populations

SUMMARY | SVANOVIR® PRV gE-Ab is a blocking ELISA for the detection of Pseudorabies/Aujeszky’s infection in vaccinated swine populations. The high specificity enables discrimination of serological response to gE-deleted vaccine strains from that of field virus. This is a great benefit for use in eradication as well as control programmes and for certifying swine for import and export.

YOUR CHALLENGE is a persisting herpes virus
The severity of the clinical manifestation in swine is age dependant, where severe disease with fatal outcome is more often seen in young piglets. In adults the disease is fairly mild and after clinical recovery persistently infected animals are a major risk for virus transmission. Control of this globally occurring disease is achieved by stamping out infected animals and/or by vaccinating swine populations at risk.

YOUR GOAL is to discriminate between antibodies from vaccination vs. field infection in animals
Efficient vaccines reduce or prevent clinical signs without necessarily preventing virus replication in individuals and herds. Marker vaccines are part of the DIVA concept (differentiating infected from vaccinated individuals) and specific diagnostic tests are an essential complement to discriminate a serological response induced by vaccination from those of field infection.

ASSAY OVERVIEW
SVANOVIR® PRV gE-Ab

<table>
<thead>
<tr>
<th>Species</th>
<th>Porcine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Samples</td>
<td>Serum/plasma, whole blood (filter paper)*</td>
</tr>
<tr>
<td>Type</td>
<td>Blocking ELISA based on full antigen, anti-gE(gI) monoclonal antibodies</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Article number</th>
<th>Samples**</th>
<th>Plates</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>104902</td>
<td>184</td>
<td>2</td>
<td>Strips</td>
</tr>
<tr>
<td>104904</td>
<td>920</td>
<td>10</td>
<td>Plates</td>
</tr>
</tbody>
</table>

* Extra protocol available on request
** Samples: Max number of samples for analysis, wells for kit controls excluded

Reliable test results
High performing test with high sensitivity and specificity
Discriminates vaccinated animals from naturally infected
Detects carrier animals from naturally infected
Standardised against the reference serum ADV-1
Field proven and used in eradication and control programmes in Europe
The SVANOVIR® PRV gE-Ab assay has demonstrated excellent performance and is a field-proven tool in the control of Aujeszky’s disease in vaccinated swine populations.

**Effective handling and convenient in use** with flexible protocol, ready-to-use reagents and alternative incubation time.


**Multilingual kit insert and labels**

**YOUR SUPPORT**

From 9am-4pm CET call:

☎ +46 18 65 49 15
✉ customer.service@svanova.com

Boehringer Ingelheim Svanova
Box 1545
SE-751 45 Uppsala, Sweden

www.svanova.com

**PERFORMANCE CHARACTERISTICS**

**SVANOVIR® PRV gE-Ab**

In several studies including well-defined samples from different epidemiological subpopulations SVANOVIR® PRV gE-Ab assay has demonstrated superior performance. The test discriminates between antibodies from vaccination and field infection. False positive results is minimised due to the high specificity of the test. The high sensitivity allows correct detection of positive animals.

<table>
<thead>
<tr>
<th>Samples</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>Reference method</th>
</tr>
</thead>
<tbody>
<tr>
<td>Commercial pigs n= 1392¹</td>
<td>100%</td>
<td>99.6%</td>
<td>VNT</td>
</tr>
<tr>
<td>Naturally infected, vaccinated, Non-vaccinated herds n= 999⁸</td>
<td>98.9%*</td>
<td>99.6%</td>
<td>DANISH BLOCKING ELISA**</td>
</tr>
<tr>
<td>Well defined samples from National reference Centerc</td>
<td>97%</td>
<td>100%</td>
<td>In-house ELISA IZSLER Brescia</td>
</tr>
<tr>
<td>Commercial pigs n= 155²</td>
<td>n.a%</td>
<td>100%</td>
<td>VNT</td>
</tr>
</tbody>
</table>

Samples originating from ¹Sweden, Yugoslavia, Germany, ²Denmark, ³Italy- National Reference Center for Aujeszky Disease - (IZLER), Brescia, Germany*, ⁴Virus neutralization test, **Sörensen and Lei (1986), J. Virol. Methods

In a study performed by the National Reference Centre for Aujeszky’s disease in Italy – on 46 well-defined samples - SVANOVIR® PRV gB-Ab showed excellent agreement with their reference method (in-house ELISA).


**Complementary product**

**SVANOVIR® PRV gB-Ab** Controlling Pseudorabies/Aujeszky’s disease in non-vaccinated swine populations